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Evaluation of a Novel Time-Efficient Protocol for
Gadobenate Dimeglumine (Gd-BOPTA)-Enhanced Liver
Magnetic Resonance Imaging
Gu¨nther Schneider, MD,* Katrin Altmeyer, MD,* Miles A. Kirchin, PhD,† Roland Seidel, MD,*
Luigi Grazioli, MD,‡ Giovanni Morana, MD,§ and Sanjay Saini, MD¶
Objective: We sought to evaluate gadobenate dimeglumine for the
detection and characterization of focal liver lesions in the unen-
hanced and already pre-enhanced liver.
Materials and Methods: Sixty patients were evaluated prospec-
tively. Unenhanced T1-weighted gradient echo (T1wGRE) and T2-
weighted turbo spin echo (T2wTSE) images were acquired followed
by contrast-enhanced T1wGRE images during the dynamic, equi-
librium, and delayed phases after the bolus injection of 0.05
mmol/kg gadobenate dimeglumine. An identical series of dynamic
images was then acquired after the delayed scan following a second
0.05 mmol/kg bolus of gadobenate dimeglumine. Images were
evaluated randomly in 2 sessions by 3 independent blinded readers.
Evaluated images in the first session comprised the unenhanced
images, the first or second set of dynamic images, and the delayed
images. The second session included the unenhanced images, the
dynamic images not yet evaluated in the first session, and the
delayed images. The 2 reading sessions were compared for lesion
characterization and diagnosis, and kappa () values for interob-
server agreement were determined. Quantitative evaluation of lesion
contrast enhancement was also performed.
Results: The enhancement behavior in the second dynamic series
was similar to that in the first series, although pre-enhancement of
the normal liver resulted in reduced lesion-liver contrast-to-noise
ratios and the visualization of some lesions only on arterial phase
images. Typical imaging features for the lesions included in the
study were visualized clearly in both series. Strong agreement ( 
0.56–0.89; all evaluations) between the 2 images sets was noted by
all readers for differentiation of benign from malignant lesions and
for definition of specific diagnosis, and between readers for diag-
noses established based on images acquired in the unenhanced and
pre-enhanced liver.
Conclusion: Dynamic imaging in the hepatobiliary phase gives
similar information as dynamic imaging of the unenhanced liver.
This might prove advantageous for screening protocols involving
same session imaging of primary extrahepatic tumors and liver.
Key Words: gadobenate dimeglumine, liver imaging, MR
protocol, MR imaging
(Invest Radiol 2007;42: 105–115)
Gadobenate dimeglumine (Gd-BOPTA, MultiHance;Bracco Imaging SpA, Milan, Italy) is a gadolinium-
based MR contrast agent with 2 unique features compared
with conventional gadolinium contrast agents. First, it pos-
sesses high r1- and r2-relaxivity in blood at all magnetic field
strengths because of weak, transient interactions of the Gd-
BOPTA contrast-effective moiety with serum albumin.1–3
Values for r1-relaxivity of 10.9, 7.9, and 5.9 L · mmol1s1
have recently been reported for gadobenate dimeglumine in
human blood plasma (37°C) at magnetic field strengths of
0.2, 1.5, and 3 T, respectively, compared with 5.7, 3.9, and
3.9 L · mmol1s1, respectively, for gadopentetate dimeglu-
mine under the same conditions.1 The increased r1- and
r2-relaxivity of gadobenate dimeglumine leads to consider-
ably greater contrast enhancement for magnetic resonance
imaging (MRI) applications in general4–9 and liver imaging
in particular.10,11 Second, gadobenate dimeglumine has a
dual route of elimination with 3–5% of the injected dose
taken up by functioning hepatocytes and eliminated in the
bile.12,13 Although the fraction eliminated through the hepa-
tobiliary pathway does not affect the overall pharmacokinetic
profile compared with other gadolinium agents,12 or the
ability to perform dynamic imaging of the liver after bolus
injection,11,14–17 the 3–5% taken up leads to a marked and
prolonged enhancement of healthy liver parenchyma18
against which primary malignant tumors and secondary me-
tastases generally appear hypointense on images acquired at
1–3 hours after injection as a result of the absence of func-
tioning hepatocytes within these lesions. Several studies have
demonstrated improved liver lesion detection on delayed
MRI with gadobenate dimeglumine.12,14–17,19,20 The value of
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delayed MRI with gadobenate dimeglumine for improved
liver lesion characterization has also been demonstrated,
particularly for the characterization of atypical focal nodular
hyperplasia (FNH)21 and for the accurate differential diagno-
sis of FNH from hepatic adenoma.22
However, although the possibility to perform delayed
hepatobiliary phase imaging has proven advantageous for
many clinical questions, the imaging protocol routinely used
at most institutions requires an interval of 1–3 hours between
the initial dynamic examination and the delayed hepatobiliary
examination. With this in mind, the present study was con-
ducted in patients with focal liver lesions to determine the
feasibility of a more time-efficient imaging protocol in which
the delayed phase examination is performed before the dy-
namic phase examination. The principal objective was to
demonstrate equivalence between the liver lesion enhance-
ment patterns observed on conventional dynamic imaging
using a standard imaging protocol, and those observed on
contrast-enhanced dynamic imaging in a previously contrast-
enhanced liver. Favorable results might positively impact the
clinical application of gadolinium contrast agents with hepa-
tobiliary properties, permitting initial screening for liver me-
tastases and, if necessary, accurate same-session dynamic
characterization of equivocal incidental lesions.
MATERIALS AND METHODS
Subjects
Sixty consecutive patients (28 men, 32 women; mean
age 52 14 years; range 27–75 years) with one or more focal
liver lesions detected at sonography and/or computed tomog-
raphy and subsequently referred for contrast-enhanced MRI
were included in the study. All patients were examined as
part of clinical routine. On the basis of all imaging findings,
30 patients were diagnosed with primary (n  9) or second-
ary (n  21) malignant lesions and 30 patients with benign
lesions.
Patients With Malignant Lesions
The 9 patients with primary malignant lesions com-
prised 6 patients with hepatocellular carcinoma (HCC; 2
patients with a single lesion only, 1 patient with a single HCC
and a pseudolesion transitory hepatic attenuation difference,
1 patient with 2 atypical HCC nodules and 2 cysts, and 2
patients each with more than 10 HCC lesions, one of whom
had alcohol-induced cirrhosis), 2 patients with fibrolamellar
carcinoma (both of whom had one or more surrounding
daughter nodules), and 1 patient with cholangiocellular car-
cinoma. The 21 patients with liver metastases comprised 4
patients with primary breast cancer (1 with a single metastatic
lesion, another with 2 lesions, and the remaining 2 patients
with more than 10 lesions each), 4 patients with primary
colorectal carcinoma (1 patient with 6 metastatic lesions, 1
patient with 3 lesions, and 2 patients with 2 lesions each), 2
patients with primary leiomyosarcoma (1 patient with a single
metastatic lesion and the other with more than 30 lesions), 1
patient with 3 metastatic lesions from primary gastric cancer
and 2 cysts, 1 patient with 7 metastatic lesions from primary
esophageal cancer, 1 patient with more than 10 metastatic
lesions from primary renal cell carcinoma, 1 patient with
more than 40 metastatic lesions from primary lung adenocar-
cinoma, 1 patient with a single metastatic lesion from primary
adenocarcinoma of the appendix, 1 patient with more than 20
metastatic lesions from an unknown primary adenocarci-
noma, 1 patient with a single intrahepatic metastasis from
previously resected cholangiocarcinoma, and 1 patient with a
single hypervascular metastasis from an unknown primary
tumor and one cyst. The remaining 3 patients with metastases
also were shown on on-site final diagnosis to have additional
benign hemangiomas. Two of these patients had primary
melanoma (1 with more than 10 metastatic lesions and 2
hemangiomas and the other with a single metastatic lesion, 2
hemangiomas and 5 cysts) whereas the third patient, who
suffered from a primary carcinoid, had 10 metastatic lesions
and 2 hemangiomas.
Patients With Benign Lesions
The most frequent lesions among the 30 subjects with
benign liver lesions were hemangioma and focal nodular
hyperplasia (FNH). Overall, 11 subjects were diagnosed with
hemangioma alone (7 patients with a solitary hemangioma, 1
of whom also had 3 cysts and another 2 cysts; 3 patients with
2 hemangiomas, 1 with both a capillary and a cavernous
hemangioma and another with an additional cyst; and 1
patient with 3 hemangiomas and a cyst). A further 6 subjects
were diagnosed with FNH alone (2 subjects with solitary
typical FNH, 1 of whom also had an additional cyst, 2
subjects with solitary atypical FNH, and 2 subjects with 3
FNH each). Two subjects were diagnosed with both heman-
gioma and FNH (one subject with 2 hemangiomas and 1
atypical FNH and the other subject with 1 hemangioma and
2 FNH). One further subject with an FNH nodule was
diagnosed principally as having adenomatosis (7 adenomas
detected on on-site final diagnosis). The remaining patients
with diagnosed benign lesions comprised 1 patient with a
solitary adenoma, 3 subjects with regenerative nodules (2
subjects with a single lesion each and one subject with 2
lesions), 1 subject with a solitary nodule of regenerative
hyperplasia, 1 subject with post-traumatic subcapsular hema-
toma, 1 subject with postsurgical bilioma and 14 cysts, 1
subject with a single inflammatory pseudotumor, 1 subject
with a single echinococcal cyst, and 1 subject with multiple
abscess formations.
MRI Protocol
All patients were studied on a 1.5 T MR unit (Magne-
tom Vision, Siemens Medical Systems, Erlangen, Germany)
at a single center using a body-array coil. MRI in all patients
was performed using T2-weighted turbo spin echo (T2wTSE)
sequences, T2-weighted HASTE (T2w-HASTE) sequences,
and T1-weighted gradient echo FLASH-2D (T1wGRE) se-
quences according to the scheme shown in Figure 1. T2-
weighted imaging was performed with both TSE and HASTE
sequences to obtain satisfactory T2-weighted images in all
patients (ie, to avoid limitations associated with compara-
tively high motion sensitivity in the case of T2wTSE se-
quences, eg, caused by bowel movement in bowel loops
adjacent to the liver and reduced lesion-to-liver contrast in the
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case of T2w-HASTE sequences, eg, in case of metastases of
colorectal tumors). Images were acquired before the adminis-
tration of gadobenate dimeglumine (unenhanced T2w and
T1wGRE images), during the dynamic phase of contrast en-
hancement after the intravenous bolus administration of 0.05
mmol/kg bodyweight gadobenate dimeglumine (T1wGRE im-
ages only, acquired at 20 to 25s arterial phase, 55 to 60s
portal-venous phase, and 3 to 5 minutes equilibrium phase
postinjection), and in a delayed hepatobiliary phase after the
administration of gadobenate dimeglumine (T1wGRE images
only, acquired at 1 hour after injection). A second bolus injection
of 0.05 mmol/kg bodyweight gadobenate dimeglumine (same
parameters as the first injection) followed by acquisition of a
second, identical series of dynamic phase images was then
performed immediately after the delayed (hepatobiliary)
scan (Fig. 1). Gadobenate dimeglumine was administered
to all patients by means of a power injector (Injektron
MRT, MEDTRON, Germany) via an antecubital vein of
the right arm at a rate of 2.5 mL/s. All injections were
followed by a 20-mL saline flush at the same rate.
Precontrast T2wTSE images were acquired with TR 
3200 milliseconds, TE  138 milliseconds. A total of 22
slices were acquired in 2 breath-holds (11 slices/breath-hold)
with an overall imaging time of 17 seconds per breath-hold.
Precontrast T2w-HASTE images were acquired with TR 
4400 milliseconds, TE  90 milliseconds, flip angle  180°.
A total of 30 slices were acquired in 2 breath-holds (15 slices
per breath-hold) with an overall imaging time of 20 seconds
per breath-hold. Pre- and postcontrast T1wGRE images were
acquired with TR  174.9 milliseconds, TE  4.1 millisec-
ond, flip angle  80°. A total of 23 slices were acquired
with an overall imaging time of 18–20 seconds depending on
the field-of-view. The slice thickness for all sequences was
6 mm with an interslice gap of 1.5 mm. A matrix size of at
least 160  256 was employed for all sequences with a
rectangular field-of-view of 350–420 mm.
Image Evaluation
Images were evaluated randomly in 2 sessions by 3
experienced off-site readers (L.G., G.M., S.S.; each with
more than 10 years’ experience in the field of liver MRI) who
were fully blinded to all information regarding the clinical
history of patients and the results of other diagnostic imaging
examinations. Images were prepared on CD-ROM and sent
by mail to each blinded reader for viewing and evaluation on
each reader’s personal computer. Image sets from each of the
60 patients were evaluated in each session. In the first session,
each reader was presented with the unenhanced T2w and
unenhanced T1wGRE images, the delayed T1wGRE images,
and either the first or second set of dynamic T1wGRE images
from each patient. In the second session, each reader was
presented with the same unenhanced and delayed phase
images but with the dynamic T1wGRE images not seen in the
first session. The randomization of image sets for the first and
second reading sessions was different and was determined by
a central study coordinator (K.A.).
Each reader in each reading session was presented
simultaneously with 6 image sets for each patient in a 3  2
arrangement on the computer screen. The upper row of
images comprised, from left to right, the T2w image set, the
unenhanced T1wGRE image set, and the enhanced T1wGRE
hepatobiliary phase image set. The lower row displayed, from
left to right according to the randomization scheme, the
arterial, portal-venous, and equilibrium phase image sets
from either the first or second dynamic series of acquisitions.
Each of the 6 image sets on the screen contained images
covering the entire liver, and the image levels were synchro-
nized for the different techniques displayed. The readers were
able to scroll through all image sets simultaneously or sepa-
rately and were able to change the window setting, perform
measurements and magnify the images.
The 3 blinded readers reported their findings for each
patient on a case report form before moving to the image sets
for the next patient. Only after the central study coordinator
had received back from a reader the CD-ROM and completed
case report forms for all 60 patients from the first reading
session was the CD-ROM for the second reading session
dispatched and the reader permitted to begin the second
reading session. The interval between reading sessions was
28 days for reader 1, 21 days for reader 2, and 23 days for
reader 3.
Each off-site blinded reader evaluated the image sets
for all patients in an identical manner. Images were evaluated
first for image quality and radiologic diagnosis (a 4-point
scale where 1  poor, 2  sufficient, 3  good, and 4 
excellent). Thereafter, each reader was asked whether any
lesion was detected on the image sets and if so, how many. If
8 or fewer lesions were detected in a patient, the readers were
asked to note the size and the liver segments in which they
appeared (in terms of the segmental anatomy of the liver
according to Couinaud23 and Bismuth24) and to record their
location on dedicated liver maps for subsequent matching
between the first and second reading sessions. If more than 8
lesions were detected, the readers were asked to record the
size and location of the 8 biggest lesions.
The enhancement patterns of lesions detected on both
dynamic and delayed phase images were then recorded. For each
lesion detected on dynamic phase images the readers were asked
to characterize the enhancement pattern observed as indicative
of a hypervascular lesion, a hypovascular lesion or a lesion
demonstrating delayed persistent enhancement. For delayed
phase images the readers were asked to decide whether the
FIGURE 1. Contrast administration and image acquisition
scheme.
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detected lesions showed signal intensity enhancement or not. If
enhancement was observed the readers were asked to decide
whether this was homogenous or inhomogenous. If lesions were
recorded as not showing enhancement, the readers were asked to
decide whether these lesions had a hypointense rim surrounding
the lesion or demonstrated signs of nonspecific peripheral wash-
out. Frequently, delayed wash-in and wash-out of contrast may
occur into central necrotic and fibrotic areas of hypovascular,
nonenhancing lesions by a nonspecific mechanism, in a manner
similar to that known from CT and from MRI with extracellular
contrast agents. Finally, on the basis of the images evaluated,
each reader was asked to make a diagnosis for each lesion
detected.
Accuracy for Lesion Characterization
The findings of the 3 blinded off-site readers were
compared with the results of the on-site final diagnoses to
evaluate the diagnostic efficacy for lesion characterization in
the unenhanced liver versus lesion characterization in the
pre-enhanced liver. For this assessment, the off-site findings
for both sets of images were compared with histology results
from either biopsy (36/60 patients, 60%; 55 lesions overall)
or surgical resection (22/60 patients, 37%; 30 lesions overall).
Lesion characterization for the remaining 2 patients was
based on follow-up (1 patient with a large typical FNH) or
autopsy (1 patient with alcohol-induced cirrhosis and more
than 10 HCC lesions; autopsy performed within 1 month of
the MR examination).
Quantitative Evaluation
Quantitative evaluation of the enhancement behavior of
lesions was performed by assessing the lesion signal intensity
relative to normal liver on pre- and postcontrast T1-weighted
images. Regions of interest (ROIs) matching the diameter of
the lesion were placed on the lesion and the surrounding
normal healthy liver parenchyma on images acquired precon-
trast and during each postcontrast phase of enhancement.
ROIs in normal liver tissue were placed to the left or right of
the lesion to avoid differences in SI caused by different
distances to the body-array coil. An additional ROI was
placed to determine the background noise. Care was taken to
position each ROI in corresponding positions on each image
set and on lesion and liver tissue whose signal intensities
were as homogenous as possible. The relative lesion-to-liver
contrast-to-noise ratio (CNR) for each lesion was determined




where SILesion  signal intensity measured at ROI positioned
on the lesion, SILiver  signal intensity measured at ROI
positioned on the liver and SDnoise  standard deviation of
noise measured at ROI on nonenhancing extrahepatic tissue
ventral to the upper abdomen.25
Statistical Analysis
Cohen’s kappa () statistics were used to determine
levels of agreement for lesion characterization for images
acquired in the unenhanced liver compared with images
acquired in the pre-enhanced liver. Determinations were
performed both for the differentiation of benign from malig-
nant lesions and for the specific diagnosis of lesions relative
to the final diagnosis for each patient. The percent agreement
for lesion diagnosis against final diagnosis was also deter-
mined for images acquired in the unenhanced liver and
pre-enhanced liver. Determinations of 3-reader agreement
were performed for all images acquired after the first bolus
injection of gadobenate dimeglumine in the unenhanced liver
and for all images acquired after the second bolus injection in
the pre-enhanced liver. Finally, evaluations were performed
for malignant lesions and benign lesions separately.
RESULTS
All image sets for all patients were considered to be of
excellent diagnostic quality by each reader and all were
included in the blinded assessments. All lesions detected
during the first imaging session were visible also during the
second imaging session. An on-site final diagnosis was avail-
able for all 60 patients. This was based on histology for 59
patients and patient follow-up for one patient.
Malignant Lesions
Good overall agreement was obtained between the
off-site blinded readers and the final on-site diagnosis for
both the first and second sets of images. Malignant lesions
that were detected but misdiagnosed as nonmalignant com-
prised a solitary metastasis from melanoma in a patient with
2 additional hemangiomas (misdiagnosed as hemangioma by
reader 1 on pre-enhanced images only), a solitary metastasis
from a leiomyosarcoma, which was misdiagnosed as hepatic
adenoma by reader 3 on both image sets and by reader 2 on
just the pre-enhanced image set, and a small (1 cm) HCC,
which tentatively was diagnosed as nonmalignant by readers
2 and 3 on both image sets. No other confirmed malignant
lesion was misdiagnosed as nonmalignant by any reader on
either of the 2 image sets.
Misdiagnoses among malignant lesions were made for
one patient with 2 atypical nodules of HCC (misdiagnosed as
metastases by all readers on both image sets), 1 patient with
cholangiocellular carcinoma (misdiagnosed as metastasis by
reader 1 on both image sets, and by reader 3 on the pre-
enhanced image set only), and 1 patient with 2 nodules of
fibrolamellar carcinoma (misdiagnosed as metastases or sim-
ply classified as “malignant” by all readers on both image
sets). Imaging features considered characteristic of malignant
lesions after contrast enhancement such as HCC pseudocap-
sule and early wash-out of contrast agent (Fig. 2) or periph-
eral hypervascularization or peripheral wash-out in metasta-
ses of colorectal carcinoma (Fig. 3) were clearly visualized
both on conventional dynamic imaging after the first injection
of gadobenate dimeglumine and on dynamic imaging in the
pre-enhanced liver after the second injection of gadobenate
dimeglumine.
Benign Lesions
The 57 benign lesions determined on on-site final
diagnosis in the 28 patients with 8 or fewer benign lesions
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comprised 19 hemangiomas, 14 FNH, 8 adenomas, 8 cysts, 4
regenerative nodules, 1 subcapsular hematoma, 1 ecchinococ-
cal cyst, 1 regenerative hyperplasia, and 1 inflammatory
pseudotumor. Complete agreement with the findings of the
on-site final diagnosis was found for both image sets for the
majority of patients with hemangioma. Among 11 patients
FIGURE 2. Multifocal HCC in a 58-year-old male patient. The unenhanced T2-weighted image (a) clearly reveals 2 focal areas
(large arrows) of hyperintensity of approximately 2–3 cm diameter each in liver segments VII and VIII. Additional small areas
of hyperintsity (small arrows) are also evident in segment IV and elsewhere. On the corresponding unenhanced T1-weighted
image (b), these lesions are markedly hypointense against the surrounding normal parenchyma. During the arterial phase at
25 seconds after the first injection of gadobenate dimeglumine at 0.05 mmol/kg bodyweight (c), the lesions appear strongly
hyperintense (arrows). However, the contrast has washed out completely by the portal-venous phase at 60 seconds (d), leav-
ing the lesions as markedly hypointense with characteristic hyperintense peripheral rims (small arrows). This pattern of en-
hancement persists into the equilibrium phase at 5 minutes after injection (e). On the delayed phase image (f), the lesions are
still strongly hypointense against the enhanced normal parenchyma although the peripheral rims can no longer be seen. Nu-
merous small lesions (small arrows) identified as focal areas of hyperintensity during the arterial phase are clearly seen as hy-
pointense during the delayed phase. A similar pattern of enhancement to that seen during the first dynamic series is seen dur-
ing a second dynamic series (g, h, and i) acquired after a second injection of 0.05 mmol/kg gadobenate dimeglumine.
FIGURE 3. Metastases in a 64-year-old male patient with primary colorectal carcinoma. The unenhanced T2-weighted image
(a) clearly reveals a large focal area (arrows) of hyperintensity of approximately 8 cm in liver segment VII. On the correspond-
ing unenhanced T1-weighted image (b), this lesion is markedly hypointense against the surrounding normal parenchyma and
a second, small hypointense area (arrowhead) is visible in liver segment VIII. During the arterial phase at 25 seconds after the
first injection of gadobenate dimeglumine at 0.05 mmol/kg bodyweight (c), the large lesion is strongly hypointense and sur-
rounded by a strongly hyperintense peripheral area (arrows). The second small lesion, not readily seen on the unenhanced
T2-weighted image, can also be depicted together with a hyperintense rim (arrowhead), in liver segment VIII, indicating an
infiltrative growth of the lesion. Both lesions are clearly seen as focal hypointense areas during the portal-venous (d) and equi-
librium (e) phases after the first injection of gadobenate dimeglumine. On the delayed phase image (f) acquired at 60 min-
utes after injection both metastases have a characteristic target appearance. A similar pattern of behavior to that seen during
the first dynamic series is seen during the second dynamic series (g, h, and i) acquired after a second injection of 0.05
mmol/kg gadobenate dimeglumine.
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with just hemangioma, discrepancies in lesion diagnosis were
noted for 3 patients by reader 1 (2 hemangiomas in 1 patient
misdiagnosed as cysts on the first image set, 2 hemangiomas
in 1 patient misdiagnosed as “unknown” on the first image set
and as metastasis and cyst on the second image set, and 1
capillary hemangioma in 1 patient misdiagnosed as “un-
known” on the second image set), for 1 patient by reader 2
(capillary hemangioma misdiagnosed as cholangiocellular
carcinoma on the second image set) and for 3 patients by
reader 3 (2 hemangiomas in 1 patient misdiagnosed as me-
tastases on the second image set, 2 hemangiomas in another
patient misdiagnosed as metastasis and cyst on the second
image set, and the capillary hemangioma misdiagnosed as
metastasis on the second image set).
Misdiagnoses among patients with just FNH were
made by reader 1 only (1 atypical FNH in 1 patient
misdiagnosed as metastasis on the first image set and
another atypical FNH in another patient misdiagnosed as
metastasis on the second image set). Examples of the
enhancement of FNH and hemangioma after the first and
second injections of gadobenate dimeglumine are shown in
Figures 4 and 5. As in the case of malignant lesions, no
differences between the first and second dynamic series
were noted in terms of the visualization of typical features
such as central scar in FNH.
Less good agreement between off-site readers and on-
site final diagnoses was seen among patients with other types
of benign lesion. A single hepatic adenoma in 1 patient (Fig.
6) was misdiagnosed by reader 1 as a metastasis on the first
image set and as an HCC or FNH on the second image set.
Similarly, a patient with 7 adenomas and a solitary FNH on
on-site final diagnosis was misdiagnosed by reader 1 as
having 6 FNH or HCC on the first image set and 4 metastases
or HCC on the second image set. The patients with regener-
ative nodules or regenerative hyperplasia were misdiagnosed
by readers 2 and 3 on both image sets as having FNH or, in
the case of a patient with a solitary regenerating nodule, as
adenoma. In the case of reader 1, the solitary regenerating
nodule was misdiagnosed as metastasis on the first image set
and as HCC or FNH on the second image set whereas the
lesions in the other patients were misdiagnosed as FNH or
hemangioma. Each of the 3 readers misdiagnosed both the
solitary inflammatory pseudotumor (reader 1 as HCC on both
image sets and readers 2 and 3 as cholangiocellular carci-
noma on both image sets) and the multiple abscesses (on all
image sets as metastases). Finally, the subcapsular hematoma
was misdiagnosed as adenoma on just the first image set by
reader 1, as sarcoma and adenoma on the first and second
image sets, respectively, by reader 2, and as HCC and
adenoma on the first and second image sets, respectively, by
reader 3.
Reader (Interobserver) Agreement
High levels of agreement were obtained by each reader
for comparisons of image sets acquired in the unenhanced
liver and image sets acquired in the pre-enhanced liver. The
overall agreement between image sets for the differentiation
of benign from malignant lesions was   0.80,   0.64,
and   0.56 (readers 1, 2, and 3, respectively) whereas
higher levels of agreement were obtained between image sets
when evaluations were based on the specific diagnosis of
lesions (  0.82,   0.89, and   0.86; readers 1, 2, and
3, respectively). Separate comparisons of image sets for
patients with malignant and benign lesions on final diagnosis
FIGURE 4. Typical FNH in a 34-year-old female patient. A large lesion (arrow) in liver segments IV and V is clearly seen as hy-
perintense against the surrounding liver parenchyma on the unenhanced T2-weighted image (a) and as hypointense on the
unenhanced T1-weighted image (b). A hypointense central scar (arrow) within the lesion in (b) is suggestive of FNH. During
the arterial phase at 25 seconds after the first injection of 0.05 mmol/kg gadobenate dimeglumine (c), the lesion appears as
strongly hyperintense with a hypointense central scar. Contrast agent pooling during the portal-venous phase at 60 seconds
(d) and the equilibrium phase at 5 minutes (e) after injection, combined with enhancement of the central scar (arrow in e) in
the equilibrium phase, is highly suggestive of FNH. During the delayed phase (f) at 60 minutes after the injection of gado-
benate dimeglumine, the lesion appears isointense to the surrounding parenchyma while the central scar is very faintly hy-
pointense. A second dynamic series (g, h, and i) acquired after a second injection of 0.05 mmol/kg gadobenate dimeglumine
reveals similar enhancement behavior to that seen during the first dynamic series although the more strongly enhanced sur-
rounding normal parenchyma during the portal–venous phase (h) results in lower lesion-to-liver contrast and earlier uptake of
contrast into the central scar.
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revealed similarly high levels of agreement. For the 30
patients with malignant lesions, kappa values of  1.0, 
1.0, and   0.89 (readers 1, 2, and 3, respectively) were
obtained for the comparison of images acquired in the unen-
hanced liver with images acquired in the pre-enhanced liver.
Agreement between image sets was similarly high for the 30
patients with benign lesions (  0.70,   0.81, and  
0.83; readers 1, 2, and 3, respectively).
Comparison between readers revealed similarly high
levels of agreement. The agreement between the 3 readers for
FIGURE 5. Atypical FNH and hemangioma in a 42-year-old female patient. The unenhanced T2-weighted image (a) reveals a
large, strongly hyperintense lesion (arrow) in liver segment II and a faintly hyperintense lesion (arrowhead) in liver segments
VII and VIII. The corresponding unenhanced T1-weighted image (b) reveals these lesions as markedly hypointense and isoin-
tense, respectively, against the surrounding normal parenchyma. During the dynamic series of acquisitions at 25 seconds (c),
60 seconds (d), and 5 minutes (e) after the first injection of 0.05 mmol/kg gadobenate dimeglumine, the lesion in segment II
demonstrates an initial nodular peripheral enhancement followed by a centripetal “filling-in” pattern of contrast enhancement
typical of hemangioma. Conversely, the lesion in segments VII and VIII shows rapid strong hyperintensity during the arterial
phase (c) followed by contrast agent pooling during the portal-venous phase (d) and an isointense appearance during equilib-
rium (e) phase. Unlike the FNH in Figure 4, there is no evidence of a central scar in the lesion in segments VII and VIII. On the
delayed phase image (f), the hemangioma is once again hypointense due to the wash-out of contrast agent while the FNH is
faintly hyperintense to the surrounding normal parenchyma as the result of the specific uptake of gadobenate dimeglumine
by the functioning hepatocytes present in FNH. Both lesions demonstrate similar enhancement patterns during a second dy-
namic series (g, h, and i) acquired after a second injection of 0.05 mmol/kg gadobenate dimeglumine.
FIGURE 6. Hepatic adenoma in a 37-year-old female patient. A large lesion (arrow) is clearly seen in liver segment VII as
slightly hyperintense against the surrounding liver parenchyma on the unenhanced T2-weighted image (a) and as isointense
on the unenhanced T1-weighted image (b). During the arterial phase at 25 seconds after the first injection of 0.05 mmol/kg
gadobenate dimeglumine (c), the lesion appears as strongly hyperintense. Thereafter, during the portal-venous phase at 60
seconds (d) and the equilibrium phase at 5 minutes (e) after injection the lesion demonstrates persistent hyperintensity due to
contrast agent pooling in a manner similar to that observed with FNH. Unlike the enhancement behavior observed with FNH,
the adenoma (arrows) is seen as hypointense against the enhanced normal parenchyma on the delayed phase image (f) ac-
quired at 60 minutes postinjection. A similar pattern of enhancement to that seen during the first dynamic series is also seen
during a second dynamic series (g, h, and i) acquired after a second injection of 0.05 mmol/kg gadobenate dimeglumine.
However, the enhanced normal parenchyma at this time results in reduced lesion conspicuity, particularly on the portal-ve-
nous (h) and equilibrium (i) phase images.
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the differentiation of benign from malignant lesions was  
0.61 for images acquired in the unenhanced liver (ie, using a
standard imaging protocol) and  0.53 for images acquired
in the pre-enhanced liver (ie, using a time-efficient protocol).
Corresponding agreement values for the specific diagnosis of
lesions were   0.77 and   0.72, respectively. When
patients with malignant and benign lesions were considered
separately in terms of specific diagnosis, the 3-reader agreement
for images acquired in the unenhanced liver was   0.66 for
malignant lesions and   0.83 for benign lesions. For images
acquired in the pre-enhanced liver the levels of agreement were
 0.68 for malignant lesions and  0.73 for benign lesions.
The percent agreement for lesion diagnosis against
on-site final diagnosis for each patient was high for each of
the 3 blinded readers for both the image sets acquired in the
unenhanced liver (75%, 81.7%, and 80% agreement; readers
1, 2, and 3, respectively) and for image sets acquired in the
pre-enhanced liver (75%, 81.7%, and 75% agreement; readers 1,
2, and 3, respectively). Slightly better agreement with the on-site
final diagnosis was noted for malignant lesions (83.3–86.7% for
images acquired in the unenhanced liver; 80–86.7% for images
acquired in the pre-enhanced liver) than for benign lesions
(66.7–76.7% for images acquired in the unenhanced liver and
for images acquired in the pre-enhanced liver).
Quantitative Evaluation
The mean lesion-to-liver CNR values on T1-weighted
images for the 4 most common histologically proven liver
lesions (HCC, metastases, FNH, and adenoma) before and
after each injection of 0.05 mmol/kg gadobenate dimeglu-
mine are shown in Figure 7. The enhancement pattern of each
lesion type on arterial phase images after the second injection
of gadobenate dimeglumine was similar to that after the first
injection of gadobenate dimeglumine although the absolute
mean CNR values for the hypervascular lesions were lower.
Similarly reduced mean CNR values on portal–venous phase
images after the second injection of gadobenate dimeglumine
reflected the higher signal intensity of the enhanced normal
liver parenchyma after the first injection of gadobenate dime-
glumine.
Regarding the individual lesion types, the metastases in
the present study were consistently hypointense to the normal
liver parenchyma whereas the HCCs showed slight hyperin-
tensity during the arterial phase after both injections of
gadobenate dimeglumine. In contrast, the benign FNHs were
consistently hyperintense to the normal liver parenchyma.
The behavior of the adenomas resembled that of the FNHs
after the first injection of gadobenate dimeglumine and during
the arterial phase after the second injection of gadobenate
dimeglumine. However, these lesions could be distinguished
from FNH on the basis of their hypointense appearance on
delayed phase images. Similar behavior for regenerating
nodules and other lesion types was noted on images acquired
after the second injection of gadobenate dimeglumine com-
pared with images acquired after the first injection although
in all cases the mean lesion-to-liver CNR values were lower.
DISCUSSION
The incidence of liver metastases among patients with
primary tumors elsewhere in the body is high: autopsy series
of patients with extrahepatic primary tumors indicate that
approximately 50% of patients have metastatic disease of the
liver at the time of death.26,27 Among the primary cancers
considered most at risk for metastasizing to the liver are
pancreatic, breast, lung, gastric, and colorectal cancer.26,28
FIGURE 7. Mean liver-lesion CNRs on T1wGRE images during the dynamic and hepatobiliary phases after the first injection of
0.05 mmol/kg bodyweight gadobenate dimeglumine and during the dynamic phase after a second injection of 0.05 mmol/kg
bodyweight gadobenate dimeglumine. The enhancement patterns are similar after both injections although the liver-lesion
CNR after the second injection is reduced because of the enhanced normal liver parenchyma. Note that the magnitude of the
CNR difference between hepatobiliary and unenhanced T1wGRE images is similar for FNH, adenoma, HCC and metastases
although FNH appear hyperintense on hepatobiliary phase images relative to unenhanced images whereas adenoma, HCC
and metastases appear hypointense reflecting the lack of Gd-BOPTA uptake into these lesions. A greater CNR difference be-
tween hepatobiliary and unenhanced T1wGRE images would have been obtained for all lesions had a dose of 0.1 mmol/kg
bodyweight gadobenate dimeglumine been administered during the first injection (see ref.18).
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Currently, MR examinations of the liver for the detection of
liver metastases usually are conducted as independent proce-
dures, distinct from the MR examination of the primary
tumor. Unfortunately, the need to perform 2 or more MR
examinations to accurately stage the extent of disease can
impact greatly both on imaging time and costs. Although CT,
particularly with multidetector systems, represents a cheaper,
easier, and more rapid technique for cancer staging, this
modality is limited by lower specificity and by the need for
ionizing radiation and relatively large doses of iodinated
contrast agent.29–31 Furthermore, multidetector CT has not
yet proven sufficiently specific for diagnosis of, for example,
primary breast cancer.32
With contrast-enhanced MRI of the breast rapidly gain-
ing acceptance for primary cancer screening, surgical plan-
ning and postsurgical follow-up,33 and potential innovations
in MRI of the lung for cancer detection,34 the possibility to
combine a contrast-enhanced MR examination of these or-
gans with a dedicated enhanced screening examination of the
liver may be of great interest. Unfortunately, the purely
extracellular nature of most gadolinium contrast agents do not
lend themselves to combined same-session imaging of both
the extrahepatic tumor and liver. Moreover, there is some
debate as to whether the detection of liver metastases is
actually improved with the use of conventional gadolinium
agents.35 Purely liver-specific contrast agents are also inap-
propriate for a procedure of this type because of their unsuit-
ability for MRI of extrahepatic tumors. Many of the draw-
backs associated with the use of conventional gadolinium
agents may be overcome with the use of gadobenate
dimeglumine which combines the properties of a conven-
tional extracellular agent with those of an agent targeted
specifically to the liver.13 Gadobenate dimeglumine is a
safe gadolinium contrast agent36,37 and is effective not
only for all applications for which conventional agents are
used4–9,14–17,35,38–41 but also for delayed, static MRI of
the liver.11,12,14–22 As a consequence, the possibility to
combine contrast-enhanced MRI of a primary extrahepatic
tumor with a delayed screening examination for liver
metastases may be feasible with this agent.
Unfortunately, the liver is not only a repository for
metastatic disease. The worldwide incidence of primary ma-
lignant HCC has increased in recent years42 whereas benign
liver tumors not requiring surgical intervention have been
observed in as many as 20% of the adult population.43 A
study by Schwartz et al44 reported the presence of small
hepatic lesions in 378 (12.7%) patients among 2978 patients
with cancer and that of these lesions approximately 80% were
presumed benign due to the lack of growth over a mean
follow-up interval of 25.6 months. Because of the relatively
high prevalence of benign lesions in the liver, it is clear that
any screening or follow-up approach for metastases should
also be able to adequately characterize lesions discovered
incidentally during the MR imaging examination.
The present study proposes a novel, time-efficient MRI
protocol for metastases screening that also permits same-session
characterization of incidentally discovered liver lesions. Specif-
ically, the present study confirms that the dynamic enhancement
patterns of common benign and malignant liver lesions are
similar and readily diagnostic regardless of whether images are
acquired conventionally in an otherwise unenhanced liver, or
after a second injection of gadobenate dimeglumine in a liver
that is already enhanced from a first injection. Using the pro-
posed protocol it may be possible to administer gadobenate
dimeglumine at 1–3 hours ahead of the liver examination either
directly to patients referred specifically for liver MRI or to
patients with a primary extrahepatic tumor for whom an addi-
tional screening examination for liver metastases may be appro-
priate. The images acquired during this screening examination
would thus be conventional T2w images and gadobenate dime-
glumine-enhanced T1w images, both of which have been shown
to improve the detection of metastases.12,14,15,17,19 Thereafter, a
second injection of gadobenate dimeglumine would be per-
formed followed immediately by conventional dynamic phase
imaging if a lesion is discovered incidentally for which addi-
tional characterization is required. However, it is important to
note that a second injection would not always be necessary:
there would be no need to administer a second dose and to
perform a dynamic MR examination in patients with no uniden-
tifiable lesions on T2w or hepatobiliary phase T1w images or in
whom only hepatic metastases are present.
Likewise, the observation of imaging features consid-
ered typical of malignant lesions such as a peripheral hypoin-
tense rim on hepatobiliary phase T1w images or a doughnut
appearance on T2w images may be sufficient to adequately
characterize lesions as malignant without recourse to the
additional information available on dynamic imaging. The
option of a second injection would be appropriate only in
patients with equivocal lesions on T2w and hepatobiliary
phase T1w images (eg, small hyperenhancing hepatomas) for
which the additional information available on dynamic im-
aging would facilitate accurate differential diagnosis. In this
regard, small hyperenhancing lesions that are not seen on
hepatobiliary phase T1w images are highly likely to be
benign in nature.22 On the other hand, certain well-differen-
tiated HCC also may take up gadobenate dimeglumine and
appear hyper- or isointense on delayed hepatobiliary phase
imaging.45 For these latter lesions, the appearance on T2w
images might imply the need for further dynamic phase
imaging or biopsy.
We emphasize that the 60 patients included in the
present study were enrolled in a consecutive manner and were
representative of a broad cross section of patients referred for
MRI of the liver in daily routine practice. There was no
preselection of patients with specific lesion types and no
exclusion of patients on the basis of imaging findings. Fur-
thermore, the 3 readers were fully blinded to all information
regarding the clinical history of patients and the results of
other diagnostic imaging examinations. Despite the wide
variety of liver diseases included in the study and the tight
control of information available to the readers, each reader
demonstrated a high level of consistency between the 2
reading sessions in the ability to detect and diagnose focal
liver lesions ( 0.56–0.89 for determinations of agreement
for diagnoses made on the basis of images acquired in
unenhanced liver and images acquired in pre-enhanced liver).
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The principal finding of the study was that lesions that
demonstrate characteristic enhancement behavior in the un-
enhanced liver after a first injection of gadobenate dimeglu-
mine invariably demonstrate similar enhancement behavior in
the pre-enhanced liver after a second injection of gadobenate
dimeglumine. In support of this finding were the results of
quantitative analyses, which revealed similar enhancement
behavior after the second injection of gadobenate dimeglu-
mine to the behavior observed after the first injection, partic-
ularly during the immediate postinjection arterial phase. The
fact that the lesion-liver CNR was lower after the second
injection can be ascribed to the higher background signal
intensity of the enhanced normal liver parenchyma.
As regards the 3 confirmed malignant lesions (2 solitary
metastases and an HCC) that were misdiagnosed at MRI, the
misdiagnosis of the small HCC may be attributed to the
absence of characteristic morphologic features which are
typically seen only in larger HCCs and to the fact that HCCs
demonstrate variable enhancement patterns on T1w im-
ages, ranging from markedly hypointense to markedly
hyperintense.45–47 In the case of the 2 misdiagnosed me-
tastases, these were from patients with primary melanoma
and primary leiomyosarcoma: primary tumors whose me-
tastases are known to be hypervascular and to demonstrate
hyperintensity compared with the normal parenchyma on
arterial phase images.48
Of particular interest was the enhancement behavior of
benign FNH and hepatic adenoma. These lesions often are
difficult to differentiate on enhanced MRI with conventional
gadolinium chelates but are readily differentiated on delayed
MRI after gadobenate dimeglumine.22 The differential en-
hancement behavior of these lesions clearly was demon-
strated both qualitatively and quantitatively in the present
study. Interestingly, off-site reader 1 who had only limited
experience of gadobenate dimeglumine was unaware of
this differential diagnostic feature and misdiagnosed all of
the adenomas in the study. Conversely, off-site readers 2
and 3 who use gadobenate dimeglumine routinely for liver
MRI successfully diagnosed all of the adenomas on both
image sets.
To note is that gadobenate dimeglumine at a dose of
0.05 mmol/kg bodyweight was used for both injections in the
study. Although gadobenate dimeglumine at this dose has
previously been shown to be equivalent to gadopentetate
dimeglumine at a dose of 0.1 mmol/kg bodyweight because
of the higher relaxivity of gadobenate dimeglumine in vivo,11
for liver screening studies conducted in conjunction with MR
imaging of the primary tumor, it is likely that a higher dose
of 0.1 mmol/kg bodyweight would be the initial dose admin-
istered. In early studies a dose of 0.1 mmol/kg gadobenate
dimeglumine was shown to produce significantly greater
enhancement of normal liver parenchyma on delayed images
compared with a dose of 0.05 mmol/kg gadobenate dimeglu-
mine.12,18 It is unclear whether a first dose of 0.1 mmol/kg
used for MRI of the primary tumor would subsequently
influence the dynamic enhancement behavior of liver lesions
after a second injection of 0.05 mmol/kg gadobenate dime-
glumine. Although it is possible a lower lesion–liver CNR
would be attained for hypervascular lesions during the arterial
phase after the second injection, it is equally possible the
greater enhancement of normal liver parenchyma before the
second injection would improve the effectiveness of the
original screening for metastases.
Currently, a standard liver imaging protocol for gado-
benate dimeglumine would involve T1w acquisitions during
the dynamic phase of contrast enhancement followed, if
additional diagnostic information is required, by acquisitions
during the delayed hepatobiliary phase between 1 and 3 hours
after administration.11,14–17 However, although such a proto-
col can maximize the amount of diagnostic information
acquired, the need to remove patients from the magnet after
the initial series of dynamic acquisitions and then reinsert
them at 1–3 hours after injection for acquisition of delayed
images may be considered a drawback, particularly in busy
institutions with a high daily throughput of patients. The
advantage of the proposed protocol is in the improved time-
efficiency and patient-friendliness of the procedure: patients
are required to enter the magnet only once and acquisition of
dynamic and delayed phase information is obtained in little
more than the time required to obtain solely dynamic phase
information with conventional gadolinium agents.
Although the present study clearly shows that similar
diagnostic information can be acquired using the modified
imaging protocol, the findings require further substantiation
particularly in patients at risk for metastatic liver disease in
whom the benefits of gadobenate dimeglumine for both
detection of metastases and characterization of incidental
lesions are likely to be most appreciated.
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